Oncology Data Advisor

The FDA's recent accelerated approval of zanidatamab marks a significant breakthrough in the treatment landscape for human epidermal growth factor receptor 2 (HER2)–positive biliary tract cancer (BTC). Following the approval, Dr. James Harding, Associate Attending Physician in the Gastrointestinal Oncology and Early Drug Development Services at Memorial Sloan Kettering Cancer Center, sat down to provide oncology clinicians with insights into its significance and implications for clinical practice.